SRC and central nervous system cancer: By utilizing potent inhibitors to target Src or p38MAPK-related signaling pathways, the proliferation and migration of glioma cells could be greatly inhibited [47]; therefore, the development of compounds targeting both Src and p38MAPK simultaneously is promising in anti-glioma therapy.